Insider Selling: Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Sells 1,500 Shares of Stock

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 1,500 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $149.12, for a total transaction of $223,680.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of NASDAQ:JAZZ opened at $150.06 on Wednesday. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56. The firm has a market cap of $8.46 billion, a P/E ratio of 12.26, a P/E/G ratio of 0.94 and a beta of 1.15. Jazz Pharmaceuticals PLC has a 12 month low of $113.52 and a 12 month high of $153.03. The company’s 50-day moving average price is $137.19 and its two-hundred day moving average price is $133.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The company had revenue of $537.70 million during the quarter, compared to the consensus estimate of $523.92 million. During the same period in the previous year, the firm posted $3.58 earnings per share. The company’s revenue was up 14.6% on a year-over-year basis. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 14.15 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of JAZZ. Commonwealth Equity Services LLC raised its position in Jazz Pharmaceuticals by 2.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,338 shares of the specialty pharmaceutical company’s stock worth $475,000 after purchasing an additional 92 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $328,000. Janney Montgomery Scott LLC lifted its position in shares of Jazz Pharmaceuticals by 5.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 7,184 shares of the specialty pharmaceutical company’s stock worth $1,024,000 after buying an additional 401 shares in the last quarter. KBC Group NV boosted its stake in shares of Jazz Pharmaceuticals by 0.9% in the 2nd quarter. KBC Group NV now owns 103,333 shares of the specialty pharmaceutical company’s stock worth $14,731,000 after buying an additional 962 shares during the last quarter. Finally, AGF Investments LLC boosted its position in Jazz Pharmaceuticals by 109.5% in the second quarter. AGF Investments LLC now owns 3,409 shares of the specialty pharmaceutical company’s stock worth $486,000 after purchasing an additional 1,782 shares during the last quarter. 89.16% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently issued reports on the stock. TheStreet raised shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. Wells Fargo & Co lifted their price objective on Jazz Pharmaceuticals from $168.00 to $186.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Piper Jaffray Companies downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $205.00 to $142.00 in a report on Wednesday, August 21st. Evercore ISI reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, November 11th. Finally, BidaskClub upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $168.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

DORCHESTER WEALTH MANAGEMENT Co Lowers Stake in Verizon Communications Inc.
DORCHESTER WEALTH MANAGEMENT Co Lowers Stake in Verizon Communications Inc.
BLB&B Advisors LLC Has $10.25 Million Holdings in Exxon Mobil Co.
BLB&B Advisors LLC Has $10.25 Million Holdings in Exxon Mobil Co.
BLB&B Advisors LLC Sells 1,070 Shares of SPDR S&P 500 ETF Trust
BLB&B Advisors LLC Sells 1,070 Shares of SPDR S&P 500 ETF Trust
Procter & Gamble Co  Shares Purchased by DORCHESTER WEALTH MANAGEMENT Co
Procter & Gamble Co Shares Purchased by DORCHESTER WEALTH MANAGEMENT Co
Verizon Communications Inc.  Shares Purchased by Candriam Luxembourg S.C.A.
Verizon Communications Inc. Shares Purchased by Candriam Luxembourg S.C.A.
DORCHESTER WEALTH MANAGEMENT Co Acquires 440 Shares of Pfizer Inc.
DORCHESTER WEALTH MANAGEMENT Co Acquires 440 Shares of Pfizer Inc.


© 2006-2020 Ticker Report